Exemestane 25mg

Exemestane 25 mg

Brand: Magnus Pharmaceuticals
Content: 30 tablets | 25 mg per tablet
Price: €38
Manufactured in: Europe

🧪 Product Overview

Exemestane 25 mg is a third-generation, steroidal aromatase inhibitor (AI) that irreversibly binds the CYP19 enzyme, producing sustained suppression of systemic estrogen. Widely used in hormonal modulation and post-cycle therapy (PCT) research, it is particularly effective for testosterone-boosting protocols and estrogen-dependent tumor investigations.

A single 25 mg dose lowers estradiol by 60–80% within 12 hours and sustains suppression for up to 48 hours due to its ~24–27 hour half-life. Studies confirm its effectiveness in raising LH, FSH, and modestly increasing endogenous testosterone without altering adrenal androgens. This compound is listed on WADA’s S4 prohibited list for hormone modulators.

✅ Key Research Highlights

Irreversible aromatase blockade:
Covalently deactivates CYP19, maintaining estrogen suppression post-clearance [ScienceDirect]

24-hour pharmacokinetics:
Half-life of 24–27 hours ensures stable once-daily dosing in long-term hormonal protocols [PubMed]

↑ Testosterone-to-estradiol ratio:
25 mg/day improved T:E ratios in male models without affecting DHEA/androstenedione [FDA data]

Bone & lipid impact (chronic use):
Long-term data show ↓ BMD and HDL↓ / LDL↑ — relevant for extended-duration studies [PubMed, PMC]

Shelf-stable & lab-friendly:
Film-coated tablets remain potent at ≤25 °C without refrigeration [ICH Stability, MSDS]

🧬 Suggested Laboratory Applications

Irreversible aromatase inhibition and estrogen-suppression modeling

Testosterone enhancement in male hypogonadism models

PCT studies for anabolic-recovery protocols

LH/FSH modulation research

Tamoxifen-resistant estrogen-tumor studies

📊 Technical Specifications

Field	Data
Chemical Name	Exemestane (INN)
Chemical Formula	C20H24O2
Synonyms	Aromasin; FCE 24304; 6-methyleneandrosta-1,4-diene-3,17-dione
Molecular Weight	296.4 g/mol
CAS Number	107868-30-4
Half-life	~24–27 hours
Detection Window	Medium-long, varies with protocol
Documented Benefits	↓ E2 by 60–80%, ↑ LH/FSH, ↑ T, stable estrogen suppression
Main Risks	↓ BMD, lipid shifts, fatigue, joint pain, hot flashes
Total Active Compound	750 mg per carton (25 mg × 30 tablets)
Shelf-life	36 months (manufacturer specification)

❄️ PubChem-Supported Research Insights

Irreversible suppression of estrogen via steroidal aromatase inhibition

Rapid E2 reduction within 12 hours of dosing

Increases T:E ratio in male subjects without disturbing adrenal steroids

Maintains hormonal control for up to 48 hours post-dose

Applied in resistant ER+ tumor model studies and androgen support trials

⚠️ Documented Research Side Effects

Common: Hot-flushes, arthralgia, fatigue, insomnia

Long-term: Bone mineral density reduction, HDL↓/LDL↑

Other: Menopausal symptoms and mood variations

Listed under WADA S4 — prohibited in all competitive levels

🧯 Handling & Compliance

For Research Use Only — Not for human or veterinary use
Store at 15–25 °C, protect from light and moisture
Purchase confirms qualified researcher status
Listed on WADA Prohibited List S4 — any exposure may result in a positive test